SCHEMBL30888512

SCHEMBL30888512

COC(=O)c1c(C)c(C)cc2c1CCC2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 7/20 0.42
▸ CYP3A4 P08684 2/20 0.41
▸ ACHE P22303 2/20 0.41
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ USP2 O75604 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MAPK1 P28482 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888649 0.81 SLC6A2 (0.41) CYP3A4ACHEKDM4EALDH1A1HPGD
SCHEMBL30888520 0.77 METAP2 (0.42) NLRP3CYP3A4ACHEKDM4EALDH1A1
SCHEMBL29284884 0.76 USP2 (0.41) NLRP3CYP3A4ACHEKDM4EALDH1A1
SCHEMBL30888605 0.76 USP2 (0.41) NLRP3CYP3A4ACHEKDM4EALDH1A1
SCHEMBL24592591 0.76 USP2 (0.45) CYP3A4ACHEKDM4EALDH1A1HPGD
SCHEMBL30888571 0.75 TAS1R3 (0.42) NLRP3CYP3A4ACHEKDM4EALDH1A1
SCHEMBL16750519 0.74 USP2 (0.46) NLRP3CYP3A4ACHEKDM4EALDH1A1
SCHEMBL15387933 0.74 ALDH1A1 (0.58) KDM4EALDH1A1HPGDMAPTPOLB
SCHEMBL29284889 0.74 ALDH1A1 (0.44) NLRP3CYP3A4ACHEKDM4EALDH1A1
SCHEMBL38663769 0.73 ALDH1A1 (0.43) CYP3A4KDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630403-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 — — EP disclosed
WO-2024121129-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 — — WO disclosed
Send feedback